Mutant Spike Proteins & Antigens for SARS-CoV-2 Variant Research
These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines
antigens
SARS-CoV-2 Antigen Protein Kits
These new kit products include SARS-CoV-2 inhibitor screening kits, antibody titer serologic assay kits, antigen detection kit, and antigen pre-coated plates
SARS-CoV-2 Antibodies and Antigens for Diagnostic Kit Development
Perfect for use in a wide range of different antibody detection methods, these antigens are customizable and available in bulk
BD Announces CE Mark of Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 Minutes
SARS-CoV-2 Assay for BD Veritor™ Plus System to be available in Europe by end of October
LGC Acquires The Native Antigen Company
Acquisition strengthens LGC’s existing product offering to the IVD sector
Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations
Avacta Group Plc Forms COVID-19 Antigen Diagnostic Collaboration with Adeptrix
Second partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high throughput COVID-19 antigen test
Collaboration to Increase COVID-19 Antigen Production for Diagnostic Kits and Vaccine Development
OXGENE and The Native Antigen Company are developing an improved, scalable approach to SARS-CoV-2 antigen manufacture
The Native Antigen Company Introduces Rubella Virus-Like Particles
Recombinant expression of Rubella VLPs offers a reliable source of reagents for consistency in immunoassay development and manufacturing